Navigation Links
ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
Date:10/12/2009

INGLEWOOD, Calif., Oct. 12 /PRNewswire/ -- ImaginAb, Inc. and BZL Biologics, LLC have concluded a sublicense of BZL's PSMA/huJ591 antibody technology for the field of diagnostic imaging for PET and SPECT. "ImaginAb is pleased to have completed this [sub]licensing agreement with BZL as we believe that huJ591 will form the basis of an excellent clinical product for the diagnosis and management of prostate cancer. BZL's technology has extensive human data, and we believe that huJ591 in conjunction with our antibody fragment technology will produce excellent imaging agents for PET," said Dr. Christian Behrenbruch, CEO of ImaginAb. Dr. Robert Reiter, Professor of Urology at UCLA and ImaginAb's Chief Medical Advisor further elaborated, "PSMA is an extremely significant target for prostate cancer and perhaps other solid tumors - we are excited to be validating antibody fragments against this target and plan to translate into the clinic in 2010."

"Our partnership with ImaginAb for antibody imaging with huJ591 is an important part of developing our PSMA intellectual property, and we believe that the imaging applications of our technology will result in a significant benefit to prostate cancer patient care by improving diagnostic accuracy and disease monitoring. We are also interested in working with ImaginAb to integrate imaging as part of a patient management paradigm for our PSMA-targeted therapeutics," commented Barry Silverstein, President of BZL Biologics.

About BZL Biologics

BZL Biologics, LLC is a privately held biotechnology company based in New York. Its lead program is based on antibody (Ab) targeting of PSMA, a unique cancer-related antigen that is present at high levels in all prostate cancers as well as the neo-vasculature of all types of solid tumors. This provides an exceptional platform on which to build very potent and exquisitely specific anti-tumor agents.

About ImaginAb

Founded in 2007 by UCLA Faculty (Dr. Rob Reiter and Dr. Anna Wu), ImaginAb, Inc. is an early-stage biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and radioimmunotherapy. The company has a significant pipeline of clinical imaging agents under development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET and microSPECT systems.

SOURCE ImaginAb, Inc.


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
2. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
3. Workforce Alliance Concludes Three-Year Biotech Training Program
4. West Concludes Agreement with Nektar
5. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
6. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
11. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... PARK, Calif., March 23, 2017  BioPharmX Corporation ... products for the dermatology market, today reported financial ... 31, 2017, and will provide an update on ... the year. "We are pleased to ... year for BioPharmX," said President Anja Krammer. "We ...
(Date:3/23/2017)... 2017  Agriculture technology company Cool Planet has closed ... conversion to commercialize its Cool Terra and Cool Fauna ... products that are simultaneously profitable as well as sustainable ... 18 months. This latest round of funding was led ... The company,s primary product, Cool Terra, can ...
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma A/S ... innovative TransCon technology to address significant unmet medical ... for the full year ended December 31, 2016. ... for our company as we broadened our pipeline ... integrated rare disease company with an initial focus ...
(Date:3/22/2017)... , March 22, 2017 ... fragmented, states a research report by Transparency Market Research ... Inc., Amgen Inc., and AbbVie Inc., accounted for a ... The prominent players in this market are focusing aggressively ... product portfolio, which is likely to lead to market ...
Breaking Biology Technology:
(Date:3/20/2017)... Pa. , March 20, 2017 PMD ... 2.0 personal spirometer and Wellness Management System (WMS), a ... Founded in 2010, PMD Healthcare is a Medical ... with a mission dedicated to creating innovative solutions that ... life. With that intent focus, PMD developed the first ...
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 ... and 23andMe , the leading personal genetics company, ... Zipongo can now provide customers with personalized nutrition plans ... and biometrics, but also genetic markers impacting how their ... Zipongo,s personalized food decision support platform uses biometrics such ...
Breaking Biology News(10 mins):